163 related articles for article (PubMed ID: 23953689)
1. Design, synthesis, biological and structural evaluation of functionalized resveratrol analogues as inhibitors of quinone reductase 2.
St John SE; Jensen KC; Kang S; Chen Y; Calamini B; Mesecar AD; Lipton MA
Bioorg Med Chem; 2013 Oct; 21(19):6022-37. PubMed ID: 23953689
[TBL] [Abstract][Full Text] [Related]
2. Crystal structure of quinone reductase 2 in complex with resveratrol.
Buryanovskyy L; Fu Y; Boyd M; Ma Y; Hsieh TC; Wu JM; Zhang Z
Biochemistry; 2004 Sep; 43(36):11417-26. PubMed ID: 15350128
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer.
Sun B; Hoshino J; Jermihov K; Marler L; Pezzuto JM; Mesecar AD; Cushman M
Bioorg Med Chem; 2010 Jul; 18(14):5352-66. PubMed ID: 20558073
[TBL] [Abstract][Full Text] [Related]
4. Old and new inhibitors of quinone reductase 2.
Ferry G; Hecht S; Berger S; Moulharat N; Coge F; Guillaumet G; Leclerc V; Yous S; Delagrange P; Boutin JA
Chem Biol Interact; 2010 Jul; 186(2):103-9. PubMed ID: 20399199
[TBL] [Abstract][Full Text] [Related]
5. X-ray structural studies of quinone reductase 2 nanomolar range inhibitors.
Pegan SD; Sturdy M; Ferry G; Delagrange P; Boutin JA; Mesecar AD
Protein Sci; 2011 Jul; 20(7):1182-95. PubMed ID: 21538647
[TBL] [Abstract][Full Text] [Related]
6. Kinetic, thermodynamic and X-ray structural insights into the interaction of melatonin and analogues with quinone reductase 2.
Calamini B; Santarsiero BD; Boutin JA; Mesecar AD
Biochem J; 2008 Jul; 413(1):81-91. PubMed ID: 18254726
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluation of potent quinoline and pyrroloquinoline ammosamide analogues as inhibitors of quinone reductase 2.
Reddy PV; Jensen KC; Mesecar AD; Fanwick PE; Cushman M
J Med Chem; 2012 Jan; 55(1):367-77. PubMed ID: 22206487
[TBL] [Abstract][Full Text] [Related]
8. Pleiotropic mechanisms facilitated by resveratrol and its metabolites.
Calamini B; Ratia K; Malkowski MG; Cuendet M; Pezzuto JM; Santarsiero BD; Mesecar AD
Biochem J; 2010 Jul; 429(2):273-82. PubMed ID: 20450491
[TBL] [Abstract][Full Text] [Related]
9. Insights into the redox cycle of human quinone reductase 2.
Reybier K; Perio P; Ferry G; Bouajila J; Delagrange P; Boutin JA; Nepveu F
Free Radic Res; 2011 Oct; 45(10):1184-95. PubMed ID: 21762045
[TBL] [Abstract][Full Text] [Related]
10. Three Australian Lepidosperma Labill. Species as sources of prenylated and oxyprenylated derivatives of piceatannol, resveratrol and pinosylvin: Melatoninergic binding and inhibition of quinone reductase 2.
Hamid K; Tran VH; Duke RK; Duke CC
Phytochemistry; 2022 Nov; 203():113396. PubMed ID: 35998831
[TBL] [Abstract][Full Text] [Related]
11. Application of open-access databases to determine functional connectivity between resveratrol-binding protein QR2 and colorectal carcinoma.
Doonan BB; Schaafsma E; Pinto JT; Wu JM; Hsieh TC
In Vitro Cell Dev Biol Anim; 2017 Aug; 53(7):575-578. PubMed ID: 28646291
[TBL] [Abstract][Full Text] [Related]
12. Mechanism-based inhibition of quinone reductase 2 (NQO2): selectivity for NQO2 over NQO1 and structural basis for flavoprotein inhibition.
Dufour M; Yan C; Siegel D; Colucci MA; Jenner M; Oldham NJ; Gomez J; Reigan P; Li Y; De Matteis CI; Ross D; Moody CJ
Chembiochem; 2011 May; 12(8):1203-8. PubMed ID: 21506232
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities.
Maiti A; Reddy PV; Sturdy M; Marler L; Pegan SD; Mesecar AD; Pezzuto JM; Cushman M
J Med Chem; 2009 Apr; 52(7):1873-84. PubMed ID: 19265439
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of a library of resveratrol analogues as inhibitors of COX-1, COX-2 and NF-kappaB.
Kang SS; Cuendet M; Endringer DC; Croy VL; Pezzuto JM; Lipton MA
Bioorg Med Chem; 2009 Feb; 17(3):1044-54. PubMed ID: 18487053
[TBL] [Abstract][Full Text] [Related]
15. Structures of mammalian cytosolic quinone reductases.
Foster CE; Bianchet MA; Talalay P; Faig M; Amzel LM
Free Radic Biol Med; 2000 Aug; 29(3-4):241-5. PubMed ID: 11035252
[TBL] [Abstract][Full Text] [Related]
16. Negative regulation of quinone reductase 2 by resveratrol in cultured vascular smooth muscle cells.
Cai JB; Zhang ZH; Xu DJ; Qian ZY; Wang ZR; Huang YZ; Zou JG; Cao KJ
Clin Exp Pharmacol Physiol; 2008 Dec; 35(12):1419-25. PubMed ID: 18671725
[TBL] [Abstract][Full Text] [Related]
17. Loss of quinone reductase 2 function selectively facilitates learning behaviors.
Benoit CE; Bastianetto S; Brouillette J; Tse Y; Boutin JA; Delagrange P; Wong T; Sarret P; Quirion R
J Neurosci; 2010 Sep; 30(38):12690-700. PubMed ID: 20861374
[TBL] [Abstract][Full Text] [Related]
18. Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines.
Kwiek JJ; Haystead TA; Rudolph J
Biochemistry; 2004 Apr; 43(15):4538-47. PubMed ID: 15078100
[TBL] [Abstract][Full Text] [Related]
19. Specific quinone reductase 2 inhibitors reduce metabolic burden and reverse Alzheimer's disease phenotype in mice.
Gould NL; Scherer GR; Carvalho S; Shurrush K; Kayyal H; Edry E; Elkobi A; David O; Foqara M; Thakar D; Pavesi T; Sharma V; Walker M; Maitland M; Dym O; Albeck S; Peleg Y; Germain N; Babaev I; Sharir H; Lalzar M; Shklyar B; Hazut N; Khamaisy M; Lévesque M; Lajoie G; Avoli M; Amitai G; Lefker B; Subramanyam C; Shilton B; Barr H; Rosenblum K
J Clin Invest; 2023 Oct; 133(19):. PubMed ID: 37561584
[TBL] [Abstract][Full Text] [Related]
20. In cellulo monitoring of quinone reductase activity and reactive oxygen species production during the redox cycling of 1,2 and 1,4 quinones.
Cassagnes LE; Perio P; Ferry G; Moulharat N; Antoine M; Gayon R; Boutin JA; Nepveu F; Reybier K
Free Radic Biol Med; 2015 Dec; 89():126-34. PubMed ID: 26386287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
